RNAi deals picking up speed

Roche and AstraZeneca have followed Merck's lead in investing heavily in the relatively new field of RNA interference gene-silencing treatments. Roche signed with Alnylam Pharmaceuticals, a biotech with expertise in RNA interference treatments, in a licensing deal that could reach $1 billion, while AstraZeneca signed a smaller deal with the U.K.'s Silence Therapeutics, worth just over $400 million. Earlier, Merck obtained its access to RNAi by buying Sirna Therapeutics for $1.1 billion.

View Full Article in:

International Herald Tribune · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA